Skip to main content
. 2023 Oct 12;42(12):1077–1085. doi: 10.1097/INF.0000000000004098

TABLE 1.

Incidence and Incidence Rate Ratios of Pediatric COVID-19 and MIS-C Hospitalizations Throughout the Pandemic

I: Cases II: Incidence Rate Per 1,000,000 Pediatric Person Months III: Incidence Rate Ratio
COVID-19 Hospitalizations Infants (<1 Year) COVID-19 Hospitalizations Children (≥1 Year) MIS-C COVID-19 Hospitalizations Infants (<1 Year) COVID-19 Hospitalizations Children (≥1 Year) MIS-C COVID-19 Hospitalizations Infants (<1 year) COVID-19 Hospitalizations Children (≥1 year) MIS-C MIS-C Adjusted for Pediatric COVID-19 Hospitalizations
wild-type (12.4 months) 66 48 75 3.4 (CI: 2.8–4.1) 2.5 (CI: 2.0–3.1) 2.2 (CI: 1.7–2.8) Ref Ref Ref Ref
Alpha (4.1 months) 17 9 26 2.6 (CI: 1.8–3.8) 1.4 (CI: 0.8–2.3) 2.3 (CI: 1.5–3.3) 0.8 (0.5–1.1; ns) 0.6 (0.3–0.9; ns) 1.0 (0.7–1.6; ns) 1.5 (1.0–2.4; ns)
Delta (6.0 months) 44 28 65 4.7 (CI: 3.7–5.9) 3.0 (CI: 2.3–4.0) 4.0 (CI: 3.1–5.0) 1.4 (1.0–1.8; ns) 1.2 (0.9–1.7; ns) 1.8 (1.3–2.5; **) 1.4 (1.0–1.9; ns)
Omicron (5.9 months) 66 45 19 7.2 (CI: 6.0–8.7) 4.9 (CI: 3.9–6.2) 1.2 (CI: 0.7–1.8) 2.1 (1.6–2.7; ***) 2.0 (1.5–2.7; ***) 0.5 (0.3–0.9; *) 0.3 (0.2–0.4; ***)
Population immunity (6.0 months) 33 6 0 3.5 (CI: 2.7–4.6) 0.7 (CI: 0.3–1.2) 0.0 (CI: 0.0–0.2) 1.0 (0.8–1.4; ns) 0.3 (0.1–0.5; ***) No cases No cases

I: Number of children with COVID-19 and MIS-C included in our study during the different phases of the pandemic, excluding patients from Curaçao and Surinam. II: Incidence rate per 1,000,000 pediatric person months. COVID-19 incidence rate was corrected for study coverage. III: Incidence rate ratio (IRR) during the different phases of the pandemic, as compared to wild-type. For MIS-C incidence rate ratio is also shown adjusted for pediatric COVID-19 hospital admissions in the different pandemic phases. IRR (95% confidence interval, P value). The P value was calculated using the z score obtained by the Poisson distribution model (P values: ≥0.05 ns, <0.05*, <0.01**, <0.001***). No MIS-C cases were observed during the population immunity phase.

MIS-C indicates multisystem inflammatory syndrome in children.